Glaukos Corp
GKOS
View Detailed Chart
116.220USD
-0.420-0.36%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
6.67BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.36%
5 Days
0.00%
1 Month
+10.28%
6 Months
+15.00%
Year to Date
-22.49%
1 Year
-23.88%
View Detailed Chart
TradingKey Stock Score of Glaukos Corp
Currency: USD Updated: 2025-12-26Key Insights
Glaukos Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 9/207 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 121.07.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Glaukos Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
16
analysts
Buy
Current Rating
121.071
Target Price
+11.63%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Glaukos Corp Highlights
StrengthsRisks
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 35.57% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 383.48M.
Undervalued
The company’s latest PE is -75.27, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 61.34M shares, increasing 0.38% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 68.06K shares of this stock.
Glaukos Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Glaukos Corp Info
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
Ticker SymbolGKOS
CompanyGlaukos Corp
CEOBurns (Thomas William)
Websitehttps://www.glaukos.com
FAQs
What is the current price of Glaukos Corp (GKOS)?
The current price of Glaukos Corp (GKOS) is 116.220.
What is the symbol of Glaukos Corp?
The ticker symbol of Glaukos Corp is GKOS.
What is the 52-week high of Glaukos Corp?
The 52-week high of Glaukos Corp is 163.710.
What is the 52-week low of Glaukos Corp?
The 52-week low of Glaukos Corp is 73.160.
What is the market capitalization of Glaukos Corp?
The market capitalization of Glaukos Corp is 6.67B.
What is the net income of Glaukos Corp?
The net income of Glaukos Corp is -146.37M.
Is Glaukos Corp (GKOS) currently rated as Buy, Hold, or Sell?
According to analysts, Glaukos Corp (GKOS) has an overall rating of Buy, with a price target of 121.071.
What is the Earnings Per Share (EPS TTM) of Glaukos Corp (GKOS)?
The Earnings Per Share (EPS TTM) of Glaukos Corp (GKOS) is -1.544.
Related Instruments
+1.30%
+0.29%
+0.03%
+0.11%
-0.49%
-0.05%
-0.13%
-0.75%
+0.67%
+0.59%
+1.91%
+0.59%
+0.34%
+0.09%
+0.04%
+0.64%
+0.26%
+0.05%
+0.26%
+0.67%
